Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $0.52, in-line with the analyst estimate of $0.52. Revenue for the quarter came in at $321.2 million versus the consensus estimate of $314.7 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.